SUMMARY REPORT FOR THE EXPERT PANEL REVIEW OF THE TOXICOLOGICAL PROFILE FOR PCBs

Prepared for:
The Agency for Toxic Substances and Disease Registry
Division of Toxicology
Atlanta, Georgia

Contract No. 205-83-0641
Work Assignment No. 9

Prepared by:
Eastern Research Group
110 Hartwell Avenue
Lexington, MA 02421-3136

December 10, 1999
NOTE

This report was prepared by Eastern Research Group, Inc. (ERG), an ATSDR contractor, as a general record of discussion for the expert panel review meeting on the Toxicological Profile for Polychlorinated Biphenyls. This report captures the main points of scheduled presentations and highlights discussions among the expert panelists. This report does not contain a verbatim transcript of all issues discussed during the meeting. Additionally, the report does not embellish, interpret, or enlarge upon matters that were incomplete or unclear. ATSDR will evaluate the panelists' recommendations and determine what modifications are necessary to the Toxicological Profile. Except as specifically noted, no statements in this report represent analyses or positions of ATSDR or of ERG.
TABLE OF CONTENTS

EXECUTIVE SUMMARY ........................................................................................................ v

1.0 INTRODUCTION ............................................................................................................. 1-1

  1.1 Background .................................................................................................................. 1-1
  1.2 The Expert Panel ........................................................................................................ 1-2
  1.3 The Expert Panel Review Meeting ............................................................................. 1-3
  1.4 Report Organization ................................................................................................. 1-4

2.0 GENERAL COMMENTS ON THE TOXICOLOGICAL PROFILE .................................. 2-1

  3.1 Format Issues .............................................................................................................. 2-1
  3.2 Content Issues ............................................................................................................ 2-2

3.0 SPECIFIC COMMENTS ON THE TOXICOLOGICAL PROFILE ..................................... 3-1

  3.1 Comments on Chapter 1—Public Health Statement ................................................... 3-1
  3.2 Comments on Chapter 2—Health Effects .................................................................. 3-3
    3.2.1 Developmental Effects ...................................................................................... 3-3
    3.2.2 Neurological Effects ......................................................................................... 3-8
    3.2.3 Children's Susceptibility ................................................................................. 3-11
    3.2.4 Endocrine Effects ............................................................................................ 3-13
    3.2.5 Cancer ............................................................................................................. 3-17
    3.2.6 Reproductive Effects ....................................................................................... 3-27
    3.2.7 Toxicokinetics .................................................................................................. 3-28
    3.2.8 Mechanisms of Action .................................................................................... 3-28
    3.2.9 Reducing Peak Absorption Following Exposure .............................................. 3-29
  3.3 Comments on Chapter 3—Chemical and Physical Information .................................... 3-29
  3.4 Comments on Chapter 4—Production, Import/Export, Use, and Disposal ....................... 3-31
  3.5 Comments on Chapter 5—Potential for Human Exposure ............................................ 3-32
  3.6 Comments on Chapters 6–9 ....................................................................................... 3-35
  3.7 Comments on Appendix A—Minimal Risk Levels ....................................................... 3-36
    3.7.1 Tryphonas Study ............................................................................................. 3-37
    3.7.2 Tilson et al. Study ............................................................................................ 3-43
    3.7.3 Rice Studies ..................................................................................................... 3-46
TABLE OF CONTENTS (Continued)

3.7.4 Additional Comments on MRLs ........................................... 3-46

4.0 REFERENCES .............................................................................. 4-1

APPENDICES

Appendix A—List of Participants

Appendix B—Agenda
# Expert Review of the Toxicological Profile for PCBs

## List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATSDR</td>
<td>Agency for Toxic Substances and Disease Registry</td>
</tr>
<tr>
<td>DSA</td>
<td>delayed spatial alteration</td>
</tr>
<tr>
<td>EPA</td>
<td>U.S. Environmental Protection Agency</td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>IARC</td>
<td>International Agency for Research on Cancer</td>
</tr>
<tr>
<td>ICD</td>
<td>International Classification of Diseases</td>
</tr>
<tr>
<td>LOAEL</td>
<td>lowest-observed-adverse-effect level</td>
</tr>
<tr>
<td>LSE</td>
<td>levels of significant exposure</td>
</tr>
<tr>
<td>MRL</td>
<td>minimal risk level</td>
</tr>
<tr>
<td>NHEXAS</td>
<td>National Human Exposure Assessment Survey</td>
</tr>
<tr>
<td>NOAEL</td>
<td>no-observed-adverse-effect level</td>
</tr>
<tr>
<td>NPL</td>
<td>National Priorities List</td>
</tr>
<tr>
<td>NTP</td>
<td>National Toxicology Program</td>
</tr>
<tr>
<td>OECD</td>
<td>Organization for Economic Cooperation and Development</td>
</tr>
<tr>
<td>PCBs</td>
<td>polychlorinated biphenyls</td>
</tr>
<tr>
<td>TEF</td>
<td>toxic equivalency factor</td>
</tr>
</tbody>
</table>
EXECUTIVE SUMMARY

A group of expert scientists extensively reviewed the Agency for Toxic Substances and Disease Registry's (ATSDR's) draft Toxicological Profile for Polychlorinated Biphenyls (PCBs), public comments on this profile, and the Agency’s proposed disposition of these comments. During a 3-day meeting, the scientists thoroughly discussed and debated the scientific rigor of the toxicological profile and its criticisms. At the end of the meeting, the panelists generally commended ATSDR on its efforts in preparing the draft profile, but they identified numerous areas where the profile should be improved.

Following is a list of the general recommendations that the expert panelists highlighted during their closing statements. An overview of the discussion that led to these recommendations and specific examples of other suggested revisions are documented throughout this report.

- The panelists recommended several improvements to the organization and presentation of the profile. Most importantly, the panelists thought the Health Effects chapter should subordinate information on route of exposure to discussions on endpoints. They also recommended that this chapter of the profile include syntheses of information using a weight-of-evidence approach to develop conclusions. ATSDR agreed to make these and other improvements to the presentation of information in the profile.

- After highlighting several sections of the profile that do not adequately characterize relevant studies, omit studies, or rely too heavily on dated information, the panelists recommended that ATSDR carefully revise parts of the Health Effects chapter to provide more accurate, balanced, and complete accounts of the past and current information on the public health implications of PCBs.
On the topic of PCB-related cancer effects, the panelists recommended that the profile document carcinogenicity classifications published by the International Agency for Research on Cancer (IARC), the National Toxicology Program (NTP), and the U.S. Environmental Protection Agency (EPA). The panelists also recommended that ATSDR improve its reviews of the occupational epidemiological studies, and compare and contrast their findings.

The panelists generally agreed that the Tryphonas study is an adequate basis for deriving a chronic oral Minimal Risk Level (MRL), but they strongly recommended that ATSDR consider other studies as a supplemental basis for the final health guidance values. Specifically, panelists thought the human studies of Michigan, North Carolina, and Dutch cohorts might be a supportive basis for a chronic oral MRL, and they thought an animal study published by Rice might be an adequate basis for an intermediate oral MRL.

Several panelists thought the profile should offer additional insight into the general population’s PCB exposures from fish consumption. They recommended that ATSDR distinguish the potential impacts of consuming fish caught in PCB-contaminated waters from those of consuming fish from supermarkets.
1.0 INTRODUCTION

In December 1998, the Agency for Toxic Substances and Disease Registry (ATSDR) released a draft updated version of the Toxicological Profile for Polychlorinated Biphenyls (PCBs) for public comment. Since then, outside agencies, scientists, special interest groups, and the public have submitted comments on the draft profile. To ensure that ATSDR adequately responds to all comments, and to evaluate the scientific merit of the profile as a whole, the Agency assembled an expert review panel of toxicologists, epidemiologists, environmental health scientists, and other experts on September 27–29, 1999, to review the disposition of comments and critique the toxicological profile itself. This report summarizes the technical discussions of the expert review panel.

1.1 Background

Before releasing a toxicological profile, ATSDR goes through great measures to ensure that the profile accurately reflects the current knowledge base of the science. These measures include various forms of scientific review. For example, every toxicological profile goes through several rounds of internal review at ATSDR (e.g., ATSDR’s Intra-Agency Minimal Risk Level Workgroup), external peer review by selected expert scientists, and a public comment period, all before being published in final form. Through this process, expert scientists, special interest groups, the public, and others are all given the opportunity to recommend revisions or additions to ATSDR’s toxicological profiles.

The Toxicological Profile for PCBs (Draft for Public Comment) has already been subject to extensive internal and external scientific review. However, given the large number of the public comments and their content, ATSDR decided to assemble an expert panel of scientists to critically review a large subset of the public comments and how ATSDR proposes to address them. The Agency also encouraged the expert panelists to comment on any section of the toxicological profile that they thought should be revised.
This expert panel review is an integral part of the overall review process for the Toxicological Profile for PCBs and is expected to lead to a greater understanding of the scientific issues related to PCBs in the environment. ATSDR plans to carefully consider the expert panelists' comments, as summarized in this report, as it finalizes the Toxicological Profile for PCBs.

1.2 The Expert Panel

To organize a comprehensive review, ATSDR identified expert scientists who do not work for the Agency and have demonstrated expertise in the chemical and physical properties of PCBs, human exposure to PCBs, or the health effects associated with PCB exposure, whether in laboratory animals or humans. These scientists included representatives from academia and various federal health and environmental agencies, and their collective expertise spanned virtually every subject matter in the draft toxicological profile. Therefore, the scientists offered a broad and balanced perspective on the wide range of public comments that ATSDR received. ATSDR distributed copies of the draft toxicological profile, the Agency's proposed disposition of the public comments, and additional relevant information to the scientists roughly 2 weeks prior to the expert panel meeting.

Additionally, several other scientists attended the expert panel review meeting, and they fell into two general categories. First, between 15 and 20 scientists from ATSDR and its profile contractor attended the meeting. These scientists primarily observed the expert panelists' discussions, but offered their own comments and asked the panelists questions periodically throughout the meeting. Second, two observers representing the industry, who ATSDR invited, attended the meeting. The observers mostly listened to the expert panel review, but were given the opportunity to make comments on every topic that was discussed.
Appendix A lists the names and affiliations of the expert panelists, ATSDR scientists, and observers who registered to attend the expert panel review meeting. Note, ATSDR invited representatives of selected special interest groups and stakeholders to attend the meeting; two attended.

1.3 The Expert Panel Review Meeting

The 3-day expert panel meeting took place at ATSDR’s Division of Toxicology conference room in Atlanta, Georgia, on September 27-29, 1999, and generally followed the agenda shown in Appendix B. Three scientists from ATSDR’s Division of Toxicology moderated the expert panel meeting: Dr. Malcolm Williams, Dr. Obaid Faroon (Chemical Manager for the Toxicological Profile for PCBs), and Dr. Chris DeRosa (Director of the Division of Toxicology).

The meeting began with introductory remarks from Dr. Henry Falk, Assistant Administrator of ATSDR, and Dr. DeRosa. Dr. Falk opened the meeting by highlighting the importance of having meaningful and accurate toxicological profiles, not only because the profiles are a critical resource for the Superfund program, but also because they are becoming more widely used in other settings. Specifically, toxicological profiles are now being used as source documents by the World Health Organization, health and regulatory scientists, and researchers and teachers. Given the importance of the Toxicological Profile for PCBs, Dr. Falk urged the expert panelists to actively participate in the meeting’s discussions. Following on these remarks, Dr. DeRosa briefly reviewed the steps ATSDR has already taken in reviewing the Toxicological Profile for PCBs (e.g., internal Agency review, external peer review, and release for public comment). He then emphasized that the expert panel review is an integral part of ATSDR’s overall scientific review of this document. After these introductory remarks, the panelists and observers introduced themselves, noting their affiliations and areas of expertise.
For the remainder of the meeting, the panelists engaged in free-flowing discussions on the various topics listed in the agenda (see Appendix B). These discussions addressed relevant public comments, ATSDR’s responses to the comments, and any other issues pertaining to the agenda items. As the agenda shows, the expert panel spent most of its time discussing how the toxicological profile described the various health effects associated with exposure to PCBs. These discussions covered non-carcinogenic and carcinogenic effects, as well as the basis ATSDR used for deriving a chronic oral minimal risk level (MRL) for exposure to PCBs. Finally, the expert panelists were encouraged to submit written comments, in case they did not have the opportunity to provide comments during the 3-day meeting.

1.4 Report Organization

During the meeting, the panelists commented both on general issues that pertain to the entire toxicological profile and specific issues for particular sections in the profile. Section 2 of this report summarizes the general issues raised by the panelists, and Section 3 summarizes the specific issues. Within Section 3, each subsection reviews the panelists’ comments on different chapters within the profile (e.g., Section 3.1 summarizes the comments on Chapter 1 of the profile, Section 3.2 summarizes the comments on Chapter 2, and so on). Section 4 of this report lists all references cited in the text. When citing specific passages in the toxicological profile, this report refers to page numbers in the December 1998 release of the draft profile for public comment.

As noted earlier, the appendices to this report include a list of the scientists who registered to attend the expert panel review (Appendix A) and the meeting agenda (Appendix B).
2.0 GENERAL COMMENTS ON THE TOXICOLOGICAL PROFILE

During the 3-day meeting, the expert panelists' discussions primarily focused on specific topics and public comments relevant to the toxicological profile. Section 3 of this report reviews salient features of these specific comments. Some of the panelists' comments, however, were relevant to the entire toxicological profile. These general comments addressed both format issues and content issues, as described below.

2.1 Format Issues

The panelists recommended that ATSDR consider modifying several aspects of the format of the toxicological profile. Most importantly, several panelists and observers thought the profile was very redundant due to the organization of the document: In the current profile, health effects are organized by route of exposure first (inhalation, oral, and dermal), and by endpoint second (e.g., death, systemic effects, reproductive effects, and so on). Noting that the health effects associated with PCBs are believed to be largely, though not exclusively, independent of route of exposure, the panelists almost unanimously recommended that ATSDR organize Chapter 2 of the profile by endpoint first, and by route of exposure second.

The panelists recommended several other changes to the format of the document. First, one panelist recommended the use of "running headers" on every page of Chapter 2, such that readers can easily find the subject matter of every page. Second, another panelist thought Chapter 2 would benefit from the use of sub-headers that clearly distinguish studies on acute, intermediate, and chronic exposures, and that distinguish different types of health effects for a given endpoint. Some panelists thought the use of sub-headers is particularly important for the section on developmental effects (Section 2.2.2.6), which discusses behavioral effects, thyroid effects, and so on. Third, one panelist recommended that every section in Section 2.2 open with one or two sentences explaining the section's contents and including cross-references to other sections, as appropriate. Finally, a panelist suggested that the profile include an index.
2.2 Content Issues

According to the expert panelists, the following issues and general comments apply to the content in various sections of the toxicological profile. The panelists recommended that ATSDR consider revising the relevant sections of the profile accordingly.

- **Synthesis of Information.** Several panelists thought the toxicological profile should be strengthened by including brief sections that synthesize the findings of various toxicological and epidemiological studies presented in Chapter 2. The panelists thought this was especially important for the Relevance to Public Health section (Section 2.5). According to several panelists, this section currently lists the results of many different toxicological studies on animals and humans, leaving the reader with the burden of drawing conclusions or identifying common themes among them. A few panelists were particularly concerned about the lack of synthesis of information on developmental effects: The panelists thought the profile merely provided a list of studies, without highlighting consistencies and discrepancies between them.

- **Omission of Relevant Studies on PCBs.** Several panelists noted that the current version of the toxicological profile does not include recently published studies on PCBs, as well as some older references. Section 3 of this report identifies specific cases where relevant references were apparently missing or not cited. Responding to this comment, representatives from ATSDR noted that studies published in 1999 and in the last half of 1998 obviously could not be included in the draft profile, since it was published in December, 1998; however, some panelists noted that selected earlier studies were not referenced. The panelists debated whether the profile should include more information on the Yusho and Yu-Cheng poisoning incidents, as Section 3.2.1 of this report describes in greater detail.
The Profile's Emphasis on Fish Consumption. Several panelists thought the toxicological profile overly emphasized, or incorrectly characterized, human exposure to PCBs through consumption of contaminated fish. One panelist explained that this exposure pathway is an important issue for certain populations (e.g., people who consume sport-caught fish from PCB-contaminated waters), but he thought the profile should not overstate this pathway's relevance to the general population.

On a related note, some panelists were concerned that the profile relies too heavily on studies of health effects among fish-eating populations and not heavily enough on studies that have identified PCB-related health effects. Though they agreed that fish-eating populations are undoubtedly exposed to PCBs, some panelists cautioned that fish-eaters are also exposed to other persistent, bioaccumulative toxicants, thus complicating efforts to attribute observed health effects in epidemiological studies specifically to PCBs.

Accordingly, some panelists thought the profile should place a lesser emphasis on the studies of fish consumption, but others thought these studies were an important part of the profile's message.

Presentation of Congener-Specific Information. A recurring topic during the meeting was the fact that the many toxicological and epidemiological studies addressed exposures to various forms of PCBs, including congeners and/or mixtures of congeners. The panelists had differing opinions on how the profile should address congener-specific information: Some panelists thought it should be presented in separate sections of the profile; others thought including the congener-specific information under the appropriate endpoints would help highlight similarities and differences between exposures to individual congeners, commercial mixtures of PCBs, mixtures of PCBs with other contaminants, and weathered commercial PCB mixtures; and one panelist suspected that including congener-specific effects throughout the profile might make the document difficult to read.
When discussing the availability of congener-specific data, the panelists raised several related issues: Citing his own research, one panelist noted that examining associations between total PCB exposure and observed health effects might mask statistically significant findings between exposure to individual PCB congeners and selected health effects. Another panelist explained that exposure at Superfund sites is primarily to weathered mixtures of PCBs, which might differ considerably from the various commercial mixtures. Finally, yet another panelist cautioned ATSDR about relying too heavily on congener-specific information, given the differing sensitivity of various PCB analytical methods.

Miscellaneous General Comments. One panelist encouraged ATSDR to use precise terminology for symptoms (effects that you cannot see, like headaches) and signs (effects that you can see, like rashes). Since symptoms technically are subjective, this panelist thought the profile should not refer to “subjective symptoms,” as it currently does, for example, on page 220.
3.0 SPECIFIC COMMENTS ON THE TOXICOLOGICAL PROFILE

This section summarizes the panelists' review of specific topics in the toxicological profile. Comments are organized by the various chapters in the profile, and comments on health effects are further classified by endpoint. Note, panelists and observers were given the opportunity to comment on every chapter in the draft toxicological profile, but the majority of their comments addressed the health effects outlined in Chapter 2.

3.1 Comments on Chapter 1—Public Health Statement

Given the number of revisions the panelists recommended to the Public Health Statement, as documented below, and the fact that the Public Health Statement is the most important chapter of the profile to certain audiences, some panelists recommended that ATSDR carefully read through and revise this entire chapter to ensure that it provides a clear and concise statement of the relevant public health issues. Specific examples of the panelists’ concerns regarding this chapter follow.

Several panelists highlighted specific passages in the Public Health Statement that were either unclear or inaccurate. For example, one panelist questioned the reasoning behind one of the opening statements in Chapter 1: “Because the health effects of PCBs are difficult to evaluate, most of the information in this document is about seven types of commercially available PCB mixtures” (pages 1 and 2). This panelist suspected that the decision to evaluate seven types of mixtures was not simply due to the complexity of evaluating PCB-related health effects. Further, another panelist questioned the profile’s definition of the half-life of PCBs in air (“the time it takes for one-half the PCBs to change into something else,” page 3), indicating that this definition does not account for fallout or other relevant removal mechanisms. As a result, the panelists recommended that ATSDR clarify its definition of half-life in the final release of the profile. Finally, yet another panelist was not convinced that a statement on the toxicity of PCB metabolites was accurate: “Some metabolites of PCBs may have the potential to be as harmful as
unchanged PCBs, but there is no conclusive experimental evidence to support this assumption” (pages 5 and 6). This panelist also recommended that ATSDR revise its statement, “If your PCB levels in these fluids are higher than the normal environmental levels, this will show that you have been exposed to high levels of PCBs” (page 10), because prolonged low-level exposure to PCBs might also explain elevated body burdens.

In addition to the specific comments, the panelists discussed the availability and implications of medical tests to characterize PCB levels in blood, body fat, and breast milk. Though the profile clearly states that routine clinical tests are not available, some panelists suggested that ATSDR include more detailed information on this topic, such as whether tests will be commercially available, how people can get tested by physicians and specialists, and how medical professionals should interpret the significance of measured PCB levels. During this discussion, several panelists indicated that the profile does not acknowledge that no treatments are currently available to reduce body burdens of PCBs. One panelist noted that PCB tests are currently available to physicians, but some testing methods have relatively high detection limits and inadequate quality assurance measures.

Noting that exposures to chemicals at waste sites have affected certain communities more so than others, one panelist recommended that the profile, particularly the Public Health Statement, address issues of differential exposures among various ethnic groups. Based on historical data on pesticides, this panelist thought African-Americans might be more likely to store PCBs in their bodies than other sub-populations, but he was not aware of such data on PCBs. To put this comment into perspective, one panelist noted that the African-American women and white women in a study of 912 North Carolinians generally had comparable levels of PCBs, though he added that this data does not reflect exposures at hazardous waste sites (Rogan et al. 1986). At the end of this discussion, ATSDR noted that the profile will address genetic
polymorphism with regards to PCB exposure, metabolism, and health effects, if relevant data exist.

General comments on the Public Health Statement included a suggestion that the chapter include a picture indicating the chemical structure of PCBs and a discussion on PCBs in breast milk and nursing. On the latter topic, some panelists questioned whether women with elevated PCB concentrations in breast milk should nurse, but others cautioned against making such statements given the potential benefits of breast feeding. A few panelists wondered if the Public Health Statement should address this topic. Finally, a panelist thought the Public Health Statement should include some information on PCB-related immunological effects, especially considering that ATSDR proposed basing its chronic oral MRL on this endpoint.

3.2 Comments on Chapter 2—Health Effects
The expert panel discussed and debated many technical issues presented in Chapter 2 ("Health Effects") of the toxicological profile. The following subsections review these discussions, organized by endpoint. The subsections are presented in the order that topics were considered during the expert panel review; this order does not reflect any judgment on which endpoints are most important or most widely debated for PCBs.

3.2.1 Developmental Effects
The panelists reviewed public comments the Agency received regarding developmental effects following oral exposure to PCBs. With few exceptions, which are noted below, the panelists generally agreed with ATSDR’s proposed approaches for responding to the comments. The observers had no comments on the profile’s review of developmental effects. Discussions on developmental effects focused primarily on the following topics:
Inclusion of Additional Studies. In response to a public comment, the panelists listed several relevant studies that are currently not included in the draft toxicological profile. These studies include the Oswego studies (Lonky et al. 1996; Stewart et al.1999), the Dutch cohort study (Huisman et al. 1995; Koopman-Esseboom et al. 1994, 1996a, 1996b; Lanting et al. 1998a, 1998b, 1998c, 1998d; Patandin et al. 1997, 1998a, 1998b, 1998c, 1998d, 1999a, 1999b; Weisglas-Kuperus 1998), the German cohort study (Winneke et al., 1998), studies published by Dr. Deborah Rice (Rice 1999a, 1999b), and the 10-year follow-up study of a cohort of children in North Carolina (Rogan and Gladen 1991). In addition, the panelists debated the need for providing more detailed analyses of two Asian poisoning incidents—a topic that is elaborated on below.

Some panelists noted that information in the aforementioned studies should have been included in the levels of significant exposure (LSE) tables and could have been relevant to developing an MRL. Overall, one panelist encouraged ATSDR to reconsider the general message of the developmental effects of the toxicological profile (i.e., “The overall evidence suggesting that PCBs may represent a developmental hazard for human health is inconclusive,” page 225), given the emerging weight of evidence provided by these additional studies. Moreover, given the range of suggested improvements for the section on developmental effects, some panelists thought future drafts of this section would benefit from additional expert review.

Yusho and Yu-Cheng Incidents. Several panelists recommended that ATSDR consider including more information on the Yusho and Yu-Cheng poisoning incidents from Japan and Taiwan, respectively, in the Toxicological Profile for PCBs. These incidents involved two populations that consumed rice oil contaminated with complex mixtures of chemicals, which included furans, PCBs, and other compounds. Analyses of these incidents are
documented in numerous journal articles (e.g., Hsu et al. 1994; Masuda 1994). The panelists offered several insights on the relevance of these studies to the profile.

First, noting that the exposed populations in these incidents consumed mixtures of chemicals, one panelist thought this study should be included in the profile to characterize possible interactive effects (e.g., synergism and antagonism) of PCBs, furans, and other chemicals. Second, panelists debated the extent to which PCBs, as opposed to furans, accounted for the observed health effects. One panelist indicated that toxic equivalency factor (TEF) calculations have suggested that PCBs accounted for at least 25 percent of the toxicity in the Yusho and Yu-Cheng incidents. For this reason, the panelist thought the toxicological profile should more prominently acknowledge the implications of the Yusho and Yu-Cheng incidents, while noting the uncertainty associated with TEF calculations. Third, the panelists debated whether the exposure concentrations for these incidents had been accurately characterized. One panelist thought the concentrations in the rice oil were extremely well documented. Others agreed, but wondered if heating the rice oil (as the residents of Yusho and Yu-Cheng did when cooking) might have changed the composition of contaminants considerably. As a result, these panelists suspected that levels of the lower-chlorinated PCB congeners might not have been completely characterized. These issues regarding the levels of contamination in the rice oil and potential exposure concentrations were not resolved. Finally, some panelists thought the toxicological profile for PCBs should at least include references to the toxicological profiles on dioxins and furans, which reportedly review the Yusho and Yu-Cheng incidents more thoroughly.

Public Comment on the Studies Published by Jacobson. One of the public comments requested that the toxicological profile provide “a more detailed and balanced summary of the limitations” of the Michigan fisheater studies published by Dr. Joseph Jacobson (Jacobson and Jacobson 1996a, 1996b; Jacobson et al. 1984a, 1985). The panelists
thought that including results from the Oswego studies in the toxicological profile might address the concerns raised in the comment, since these studies replicate the findings of the Jacobson studies under question.

A panelist who is a principal investigator of the Oswego studies then summarized major findings from his research (Lonky et al. 1996; Stewart et al. 1999). He explained how his series of studies overcomes many of the criticisms of Dr. Jacobson's earlier studies, such as control for confounding variables, quality of sample, and representativeness of analytical data. As a result, this panelist thought inclusion of his studies in the toxicological profile would provide a much more compelling case for links between PCB exposure and neurodevelopmental effects.

Public Comment on Paneth’s Criticism of the Jacobson Studies. One of the public comments suggested that ATSDR's interpretation of Paneth’s critique of the Michigan fisheater studies (see page 125 of the profile) was misleading (Paneth, 1991). ATSDR’s disposition of comments defended its original text by noting that “many other well known researchers,” in addition to Paneth, have criticized the Michigan fisheater studies. The panelists discussed this comment and ATSDR’s response at length. One panelist recommended that ATSDR’s disposition of comments cite individual scientists and their relevant reviews, rather than simply citing “well known researchers.”

Two panelists were surprised at the extent to which the profile stands by Paneth’s criticisms of the Michigan fisheater study. Noting that Paneth apparently misunderstood the scope of the Michigan fisheater study (e.g., by assuming that the Michigan study was a case-control study, which it was not), one panelist thought ATSDR should more carefully review Paneth’s criticisms. Agreeing with this sentiment, another panelist thought ATSDR gave an imbalanced account of developmental effects by citing Paneth’s criticisms of
various studies without citing other reviews that refute these criticisms. None of the panelists echoed Paneth's criticisms of the Michigan fisheater study.

- **Recommended Revisions to the Discussion of Neurodevelopmental Effects.** One panelist thought the profile's review of developmental and behavioral effects in animals was very vague and imprecise. As an example, the panelist noted that several passages in this section of the profile discussed how studies observed "a change" or "a behavioral effect," rather than describing the effects and changes in greater detail (e.g., "an impairment" or "an improvement"). This panelist thought ATSDR should include more specific terminology throughout this section for it to be more informative to the reader.

- **The Need for Better Synthesis of Information.** Several panelists were concerned that the toxicological profile, particularly the section on developmental effects, provides little or no synthesis of the information from the many studies presented. Some panelists thought many readers might not be able to identify or understand consistencies and inconsistencies among the myriad toxicological and epidemiological studies. As an example of how the document could better synthesize information, one panelist noted that some animal and human studies have reported similar findings regarding the effect of PCB exposure on delayed spatial alteration (DSA), a spatial learning and memory task. This panelist thought the profile should highlight such parallels between human and animal studies as converging evidence on the link between PCBs and selected health outcomes.

Another panelist thought Section 2.5 (page 224) does not adequately distinguish the implications of transplacental and breast milk exposure. This panelist thought the profile should emphasize that transplacental transfer occurs at the earliest stage of life, when humans are particularly prone and susceptible to the potential effects of exposure to environmental contaminants, while breast milk exposure occurs slightly later in life.
Public Comment on the Findings Reported by Pantaleoni et al (1988). One public comment suggested that passages on pages 131, 133, and 224 of the profile do not accurately characterize the findings reported by Pantaleoni et al., but the panelists disagreed with the comment and agreed that ATSDR has accurately described this study.

Comments on the Mechanisms for Developmental Effects. One panelist offered three recommendations for improving the profile's discussion on mechanisms for developmental effects. First, this panelist thought Section 2.4.2 implies that neurotoxic effects are linked to exposures to only ortho-substituted PCB congeners, and not to other PCB congeners; the panelist did not think evidence existed proving that non-ortho-substituted congeners do not exhibit neurotoxic effects and recommended that this point be clarified. Second, this panelist thought effects of long-term potentiation might be a more relevant model for evaluating mechanisms of neurotoxicity (as opposed to nerve cell death or reduction in dopamine levels), since these effects appear to follow exposures to doses similar to those encountered in the environment. The panelist noted that some researchers (e.g., Winneke) have examined this mechanism. Third, this panelist recommended that relevant information on mechanisms and in vitro studies should be included for perspective in Section 2.2 of the profile, rather than keeping this information only in Section 2.4.

3.2.2 Neurological Effects

The panelists reviewed ATSDR’s disposition of five public comments regarding neurological effects following both inhalation and oral exposure to PCBs. One observer commented on neurological effects, as noted below.

Distinction Between Neurological Effects and Developmental Effects. A public comment, and several panelists, wondered why certain studies on neurological effects are presented in Section 2.2.2.6 (Developmental Effects) and others are presented in Section
2.2.2.4 (Neurological Effects). In response, the Chemical Manager explained the hierarchy ATSDR follows when classifying effects in toxicological profiles: Any effect observed between conception and maturation is considered a developmental effect, regardless of whether the effect was neurological, systemic, and so on. Though the panelists did not question this approach, several thought the profile should clearly state ATSDR's criterion for classifying neurological effects in two different parts of the document.

Public Comment on the Weight of Evidence for Neurological Effects. Two public comments identified inaccuracies and misleading statements throughout Section 2.2.2.4 and questioned whether sufficient evidence is available linking PCB exposures to neurological effects. A panelist who has conducted her own research on PCB-related neurological effects agreed that this section includes gross inaccuracies and cited as examples misleading statements in the first two sentences of Section 2.2.2.4 (page 117). First, this panelist thought the opening sentence, which indicates that neurotoxic effects have occurred among Native Americans who eat PCB-contaminated fish, should include a reference; this panelist was unaware of any research that had reported such a finding. Second, this panelist took exception to how the second sentence of this section characterizes her own research (Schantz et al., 1996). This sentence currently implies that her study found evidence of neurological effects among adults in a fish-eating population and that behavioral outcomes were found to be linked to exposures to ortho-substituted PCBs. However, this panelist explained that her study did not report any neurological outcomes nor links between outcomes and exposure to ortho-substituted congeners. She thought these and other inaccuracies need to be corrected, because they currently imply that studies have found evidence of neurological effects in adults. Overall, this panelist did not think sufficient evidence existed linking neurological effects in adults with exposure to PCBs.
Other panelists also addressed these public comments. One panelist thought, and others agreed, that some peer-reviewed papers from the Yusho and Yu-Cheng incidents have reported PCB-related neurological effects in adults, including numbness and nerve conduction delays (Chen et al. 1985a; Chia and Chu 1984, 1985). An observer, on the other hand, recommended that ATSDR not include the Asian poisoning incidents under the review of neurological effects, given the uncertainties associated with attributing toxic effects to both the PCBs and furans in the contaminated rice oil. Another panelist recommended, and an observer agreed, that ATSDR review the occupational medicine literature relative to PCBs for more information on potential neurological effects. The observer, however, believed that the occupational medicine literature does not provide evidence of PCB-related neurological effects. Yet another panelist thought the profile should carefully state the overall conclusion for neurological effects: This panelist encouraged that the profile indicate that not enough evidence is available to determine the links between PCB exposure and neurological effects, if any, rather than imply that no such links exist.

• Public Comment on Neurological Effects Linked to Inhalation Exposure. One comment suggested that Section 2.2.1.4 does not accurately portray findings of the three studies on neurological effects following inhalation exposure to PCBs (Fischbein et al., 1979; Emmett et al., 1988a; Smith et al., 1982). According to the disposition of comments, ATSDR plans to revise this section of the profile accordingly. The panelists had no comments on this topic.

• Public Comment on the Neurotoxicity of Ortho-Substituted Congeners. One public comment questioned the profile’s implications that only ortho-substituted PCB congeners are neurotoxic (see page 117, for example). A panelist proposed that ATSDR address this comment by considering studies on long-term potentiation effects, which reportedly are
observed following exposures to both ortho-substituted and coplanar PCBs. No other comments were offered.

3.2.3 Children’s Susceptibility

The panelists reviewed the four public comments on children’s susceptibility to PCBs. An overview of the panelists’ views on the public comments, plus some general comments on the Children’s Susceptibility section of the profile, follow. The observers had no comments on this topic.

- **Public Comment on the Relevance of Children’s Susceptibility for PCBs.** A public comment indicated that the toxicological profile overemphasizes children’s susceptibility to PCBs and that the potential health risks to children are no greater than those to adults. Several panelists, however, thought this comment has little substance, for various reasons. First, one panelist noted that children do consume elevated levels of PCBs from breast feeding—a route of exposure that obviously does not affect adults. This panelist also believed that some dietary surveys suggest that children consume more PCBs per body weight than adults. According to another panelist, some recent unpublished data indicate that children who live near selected PCB-contaminated sites have higher PCB tissue concentrations than adults. Given recent studies showing adverse health effects in children associated with low doses of PCBs (see Section 3.7 of this report) and the overwhelming evidence for developmental sensitivity in animal studies, one panelist recommended that ATSDR simply reject the public comment.

- **Public Comment on the Implications of Children’s Susceptibility on the MRL.** A public comment suggested that ATSDR not use an uncertainty factor of 10 that accounts for children’s susceptibility when developing its chronic oral MRL. (Note, ATSDR’s derivation of the MRL in the draft toxicological profile does not include such an
uncertainty factor.) When responding to this comment, the panelists and ATSDR discussed at length the scientific basis for uncertainty factors, ATSDR's approach to, and requirements for, considering uncertainty factors, and the distinction between uncertainty factors and margins of safety. One panelist was concerned that health effects are currently occurring at exposure doses comparable to the proposed MRL. At the end of the discussion, some panelists recommended use of additional uncertainty factors for the purpose of being protective of children, and others did not. The panelists revisited this topic when reviewing the basis for ATSDR's proposed MRL (see Section 3.7 of this report).

- **Public Comment on the Criticisms of the Michigan Fisheaster Studies.** A public comment suggested that Section 2.7 of the toxicological profile overstates the value of the Michigan fisheater studies. Consistent with their earlier comments regarding developmental effects (see Section 3.2.1 of this report), the panelists again disagreed with the comment's implication that the findings of the Michigan studies are erroneous.

- **Public Comment on Metabolism of PCBs by Breast-fed Infants.** A public comment questioned whether the profile's reference to studies from 1966 and 1977 (page 239) regarding metabolism of PCBs by infants might be outdated and wondered whether pediatricians still prescribe novobiocin, an antibiotic that reportedly inhibits glucuronyl transferase activity (Gartner and Arias, 1966; Leeder and Kearns, 1977). One panelist suspected that relevant studies are not available from the current literature, but he basically found the comment irrelevant, since he thought breast milk does not contain metabolizable PCBs. Another panelist noted that relatively small amounts of metabolizable PCBs are occasionally detected in breast milk, presumably shortly after an exposure.
General Comments on Children's Susceptibility. After reviewing the public comments on children's susceptibility to PCBs, some panelists offered general remarks on this topic. Two panelists thought the children's susceptibility section should acknowledge the sensitivity of the thyroid system (see Section 3.2.4 of this report), though neither cited published studies reporting a link between PCB exposure and thyroid effects in children. Another panelist indicated that the recent studies by Deborah Rice should also be included in the children's susceptibility section (Rice, 1999a; 1999b).

3.2.4 Endocrine Effects

The panelists reviewed ATSDR's disposition of every comment the Agency classified as specifically addressing endocrine effects of PCB exposure. The observers had limited comments on these discussions.

Inclusion of Additional Studies. When reviewing the public comments on endocrine effects, the panelists listed several studies that ATSDR should consider incorporating in the toxicological profile. One panelist thought the profile should include more data from human studies, specifically the Yusho incident and the pending Dutch studies (Koopman-Esseboom et al. 1994; Nagayama et al. 1997; Weisglas-Kuperus 1998), to provide a more complete account of endocrine effects. This panelist thought data from the Yusho incident provides insight on potential interactive effects between PCBs and other compounds. Another panelist thought the profile should more prominently acknowledge in vitro studies of PCB congener-specific activities, human cell lines, and so on. Yet another panelist recommended, and an observer agreed, that the profile should address Arnold's studies of endometriosis (Arnold, 1996) and Helzlsouer's studies of breast cancer (Helzlsouer et al., 1999).
Organization, Prioritization, and Synthesis of Endocrine Effects in the Profile. In response to a public comment regarding the profile's redundant discussions of endocrine effects, panelists noted that ATSDR could address this comment by revising the profile's format, as described in detail in Section 2.1 of this report. In addition, one panelist felt the profile placed too much emphasis on studies on endometriosis and breast cancer and not enough emphasis on thyroid effects, for which extensive animal studies and limited human studies are reportedly available. Given the large volume and complexity of information on endocrine effects, two panelists thought the toxicological profile should include a brief integration and synthesis of the many studies reviewed.

Public Comment on the Xenoestrogen/Breast Cancer Theory. A public comment recommended that the discussion of xenoestrogen/breast cancer theory (pages 233 and 234) be deleted from the toxicological profile. The panelists debated at length the utility of including various theories linking PCBs to breast cancer, as described below. Overall, one panelist did not think the toxicological profile should include such theoretical discussions given that scientists have little understanding of the endocrine causal pathway for breast cancer. Other panelists thought the discussions were relevant to the toxicological profile, but recommended that ATSDR move them into the profile's sections on cancer. (In fact, the panelists continued to discuss this topic in their review of the sections on cancer; see Section 3.2.5, below, for additional comments.)

The panelists provided several different perspectives on the theory of PCBs and breast cancer. One point of agreement was that the draft toxicological profile presents a very selective review of the current literature on breast cancer and environmental contaminants; one panelist noted that the profile omits a recent study that found no association between PCB serum concentrations and breast cancer (Helzlsouer et al., 1999).
Though the panelists also generally agreed that the relevant epidemiological studies currently do not support a link between PCB exposure and breast cancer, they offered different reasons for why no such link is apparent. For example, one panelist noted that the causal pathway for breast cancer might begin very early in life, in which case, studies that examine PCB levels in adult subjects would naturally not capture the exposures that might be of greatest concern. Alternatively, other panelists noted that the epidemiological studies generally have inadequate characterization of serum levels of PCBs: Emphasizing that some PCB congeners are estrogenic and others are anti-estrogenic, one panelist thought studies that reported serum levels of total PCBs are inadequate, since this metric does not characterize the estrogenicity of the exposure concentrations; another panelist indicated that some epidemiological studies collected too few serum samples (and not at relevant times) to provide a meaningful data analysis; and yet another panelist noted that many of the epidemiological studies did not consider serum levels of dioxins and furans, which might be confounding factors in establishing links between PCBs and breast cancer. The expert panelists’ varying comments and criticisms suggested that the available human studies offer little insight into the exact role PCBs have, if any, in causing breast cancer.

Public Comment on the Mendola Study (1997). A public comment noted that the shortened menstrual cycles observed in women who consumed fish, as documented in the Mendola study, cannot be attributed to PCB exposure, since the fish likely contained other persistent toxins. One panelist agreed with the comment, but thought research like the Mendola study is still germane to the toxicological profile, even though the findings might indicate results of interactive effects of many contaminants. This panelist recommended that ATSDR retain such studies in the toxicological profile and bring the associated issue of interactive effects to the forefront.
• Public Comment on the Mendola (1997) and Gerhard (1998) Studies. A public comment suggested that the studies published by Mendola and Gerhard should be deleted from the toxicological profile because they do not provide direct evidence of PCB-related endocrine effects. Disagreeing with the comment, one panelist recommended that the studies be retained in the profile with appropriate caveats noting their limitations; this panelist also suggested reinforcing the findings of these studies with relevant animal studies, if available. No other panelists addressed this public comment.

• Comments on Thyroid Effects. Two panelists thought the toxicological profile should have included more information on thyroid effects. These two panelists noted that current research has not reported consistent thyroid effects associated with exposures to PCBs: Different effects are observed in different human cohorts, thus underscoring the complexity of understanding the mechanisms of thyroid effects. Though these panelists acknowledge that inconclusive data are available for humans, they recommended that the profile review the available information. One panelist recommended that ATSDR refer to a recent issue of Environmental Health Perspectives for a review of relevant epidemiological studies that might provide additional information on thyroid effects (Brouwer et al. 1999).

• Inclusion of Discussions on Diabetes and the Pancreas as a Target Organ. Though he acknowledged that only limited information is available on these topics, one panelist was concerned that the toxicological profile does not discuss possible links between PCB exposure and diabetes, nor does it mention the pancreas as a target organ. This panelist noted that PCBs have been found to cause beta cells in the pancreas to release insulin. He then recommended that the profile at least mention potential links between PCBs and diabetes as an emerging issue, especially given the growing evidence of links between dioxin exposure and diabetes compiled by the National Institute of Health Sciences.
• Additional Comments on the Endocrine System. Some panelists thought the profile should review studies that have characterized PCB concentrations in follicular fluids, which could have implications for various target organs and effects. Others thought the profile erroneously classifies all coplanar PCBs as anti-estrogens (see page 234); these panelists indicated that some coplanar PCBs (e.g., possibly PCB #77 and #126) and their metabolites are actually estrogenic.

3.2.5 Cancer

The panelists discussed at length the public comments regarding how the toxicological profile documents PCB-related cancer effects, during which the observers offered a few comments. An overview of the panelists’ discussion follows.

• Public Comment on the Carcinogenicity of PCBs. A public comment took exception with a passage in the toxicological profile that claimed “most of the epidemiological studies have been inconclusive or have not shown an association between PCBs and cancer” (see page 138). In their discussions, the panelists unanimously agreed that ATSDR should, throughout the toxicological profile and disposition of comments, simply refer to the carcinogenicity classifications made by the U.S. Environmental Protection Agency (EPA), the International Agency for Research on Cancer (IARC), and the National Toxicology Program (NTP). The panelists encouraged that ATSDR review these classifications carefully and even incorporate EPA’s, IARC’s, and NTP’s specific terminology regarding cancer effects in humans and animals.

During this discussion, a panelist indicated EPA’s current position on the carcinogenicity of PCBs: PCBs are probable human carcinogens, based on suggestive but inadequate human studies, and animal studies that provide sufficient evidence. This panelist was surprised
that the toxicological profile currently implies that there is no association between PCBs and cancer, rather than paralleling EPA’s position.

Citing a different quote in the profile ("The weight of evidence does not support a causal association for PCBs and human cancer at this time," page 227), one panelist suggested that ATSDR use precise terminology and clearly differentiate discussions of causation from those of association when commenting on the carcinogenicity of PCBs. Another panelist indicated that the Public Health Statement (Chapter 1) does not clearly communicate the current state of knowledge regarding PCBs and cancer. Yet another panelist was concerned about the overview of PCBs and cancer in the section on Relevance to Public Health (Section 2.5). These panelists thought, and others agreed, that ATSDR needs to carefully revise the profile to avoid presenting a confusing, inconsistent account of carcinogenicity.

**Public Comment Providing Evidence that PCBs Are Not Carcinogens.** One public comment suggested that the toxicological profile should conclude that PCBs are not human carcinogens, based partly on the fact that similar cancer endpoints have not been reported across the many different epidemiological studies. The panelists generally disagreed with this comment, for two reasons. First, the panelists noted that IARC’s carcinogenicity classification clearly contradicts the comment’s assertion.

Second, a couple of the panelists explained that the observation of common cancers across studies is not a necessary and sufficient condition for establishing a contaminant’s carcinogenicity. In fact, these panelists noted that the absence of consistent cancer outcomes might simply reflect the small cohort sizes in certain studies, the extremely low incidence of certain cancers, or latency effects. Further, noting that animal studies have reported gender differences in cancer effects, one panelist hypothesized that the varying
demographics in the cohort studies might account for part of the apparent inconsistency in cancer outcomes. Finally, one panelist was not surprised about the variable cancer outcomes, given the fact that the occupational studies considered (1) notably different plant settings, (2) employees with widely varying contacts with PCBs, and (3) exposures to different Aroclor mixtures and other contaminants. In short, the panelists did not agree with the arguments provided in the public comment.

Inadequate Review of Occupational Epidemiological Studies. After citing several instances where the toxicological profile made uninformed criticisms of his epidemiological studies, one panelist recommended that ATSDR carefully review all of the profile’s discussions on occupational epidemiological studies before releasing the final draft. In general, this panelist was particularly concerned that the profile characterized what he thought were strengths in his study as either weaknesses or limitations (Sinks et al., 1992). More specifically, he thought the profile unfairly criticizes the selection criteria used in his epidemiological study (see pages 39 and 40), and he defended the criteria as a strength, rather than a limitation. This panelist noted that the criteria (e.g., including all plant workers in the study, regardless of their duration of employment) were entirely appropriate for investigating potential dose-response patterns, which would not have been possible if other selection criteria were adopted.

Expanding on these concerns, another panelist identified cases where the profile unfairly criticized “limitations” of Brown’s epidemiological studies (page 36) (Brown 1987; Brown and Jones 1981). This panelist did not see a flaw in “combining two plants from different geographical regions,” especially because the Brown study reported results for both the combined populations and for the individual plants. This panelist also disagreed with the profile’s statement that “... the appropriateness of grouping liver, biliary, and gall bladder cancers is questionable,” partly because International Classification of Disease (ICD)
codes, especially ICD codes for subjects who died more than 30 years ago, might actually support grouping these cancers. The panelist recommended that ATSDR verify whether splitting the cancers would have been defensible before citing this approach as a limitation.

In addition to the previous concerns, some panelists suggested that ATSDR's review of occupational studies comment more specifically on the differences in exposures from one plant to the next. A panelist explained that exposures at the Bloomington plant (a facility considered in one of the studies) were likely considerably different from the exposures at General Electric's plants, due to the plants' differing building configurations, industrial processes, and so on. Echoing this concern, another panelist noted that the plants she has studied use widely varying amounts of chlorinated solvents and other chemicals that should be considered when interpreting results from these types of studies.

On another note, two panelists cautioned ATSDR about classifying occupational studies by route of exposure, since employees at many plants were exposed to PCBs through some combination of inhalation, oral, and dermal exposures, and the dominant route of exposure could have varied from subject to subject. One of these panelists noted that some of the epidemiological studies currently classified under oral exposure might actually be better classified under inhalation exposure. Both panelists thought the profile should at least acknowledge that most subjects in these studies had multiple exposure routes.

By the end of the meeting, several panelists recommended that the final toxicological profile address cancer retrospective cohort mortality studies more thoughtfully and that the revised profile portray the strengths and limitations of these studies more accurately.

The Need for a Comparative Overview of Occupational Cohort Studies. Some panelists strongly recommended that the profile include a table that compares and contrasts...
key features of the many occupational cohort studies published on PCBs. The panelists noted that such a table should at least clearly indicate exactly what populations were considered in the cohort studies (some different studies actually considered the same cohorts), the location(s) of the cohorts, the availability of dose information, the type of study (prospective versus retrospective), and possibly a brief summary of findings.

The panelists thought such an addition was necessary because even researchers familiar with the literature can get easily confused when trying to make sense of the occupational studies. As an example, one panelist noted that David Brown has published more than one paper that has reported elevated liver and rectal cancers among women who were highly exposed to PCBs (Brown 1987; Brown and Jones 1981), but these papers reportedly document effects observed among a single cohort and not three separate cohorts. The panelists worried that an observer unfamiliar with this literature might interpret the results of these three papers as a consistent finding among separate studies, when, in fact, the papers present a single finding that has been observed in one cohort. The panelists thought the profile should not be ambiguous in this regard.

• **Organization of the Discussions on Cancer.** Noting that he had difficulties quickly identifying the profile's review of PCBs and brain cancer, one panelist recommended that the profile have just one section in Chapter 2 on cancer, with separate sub-sections that address the different types of cancers. Further, some panelists thought the profile should adopt a more systematic approach for presenting the studies relevant to cancer, possibly by presenting occupational studies first, followed by non-occupational studies, studies evaluating exposures from fish consumption, case-control studies, and animal studies.

• **Lack of Emphasis on Gender Differences.** During their discussions, the panelists identified several instances where gender differences were apparent, but not documented in
the profile. For instance, some of the human studies have found notable gender differences, as have selected animal studies (Mayes et al., 1998). As a result, some panelists thought discussion of gender differences should not be limited to the LSE tables, but should also be discussed in the text on cancer effects, and possibly in the Relevance to Public Health or Public Health Statement sections.

• **Public Comment on the Implications of the Most Recent Kimbrough Study.** Citing quotes from a press release that reportedly overstated the findings of the recent Kimbrough cancer study (Kimbrough et al., 1999), a public comment suggested that ATSDR carefully review this study in the final profile. When discussing this comment, copies of a recent letter to the editor criticizing the Kimbrough study (prepared by ATSDR scientists) were distributed to the panelists (Bove et al., 1999). Representatives from ATSDR gave an overview of their findings, after which panelists commented on the Kimbrough study. One panelist noted that some of the limitations identified in ATSDR’s review are simply inherent limitations in cohort mortality studies, but this panelist did question some of the data interpretations cited in the Kimbrough study. As an example, this panelist thought the study’s data are suggestive of female intestinal cancer—a conclusion that is apparently not reached in the paper.

• **Public Comment on Links Between PCBs and Melanoma.** A public comment indicated that the profile overstates the association between PCBs and melanoma that was reported by Loomis et al (1997). The panelists disagreed with this comment, noting that Loomis’ analysis of dose-response was an accurate depiction of the cancer outcomes, contrary to the arguments presented in the comment. Moreover, some panelists noted that consistent findings from another study (i.e., Sinks et al., 1992) provide compelling evidence for the association, despite the known genetic and behavioral risks of melanoma.
Public Comment on the Profile's Characterization of Breast Cancer Studies. A public comment criticized the profile for providing inaccurate and incomplete information on the association between PCBs and breast cancer in humans. When reviewing ATSDR's proposed disposition of this comment, the panelists revisited many of the topics they discussed during their earlier review of endocrine effects (see Section 3.2.4 of this report).

In general, the panelists agreed on some aspects of the profile's review of breast cancer, but disagreed on others. The main point of agreement was that the profile should discuss breast cancer primarily in the "Cancer" sections and not in the "Endocrine Effects" sections. Another point of agreement was that the profile does not provide a balanced review of the current scientific literature, but the panelists had differing recommendations for how ATSDR should address this. Some panelists thought the profile should include a more thorough review of the various studies on breast cancer, reflecting the differing quality of these studies. Several panelists, on the other hand, thought including additional information was unnecessary, suspecting that a thorough review of the literature on breast cancer and PCBs would take too much room in the profile on a topic that is still widely debated.

The main point of contention was whether the toxicological profile should discuss the xenoestrogen/breast cancer theory in the first place. Consistent with their earlier debates, some panelists thought the theory should be omitted from the profile, but others disagreed and thought the profile should briefly mention the theory, along with its uncertainties.

As general comments on PCBs and breast cancer, one panelist recommended that ATSDR integrate summary statements from Hunter's recent review article on breast cancer (Hunter et al. 1997). Another panelist thought the profile should indicate that some genetically vulnerable populations might be more susceptible to carcinogenic effects, which might
explain some of the variable results from the epidemiological studies. Other panelists questioned whether the Public Health Statement (page 7) should claim that PCBs "may play an import role in causing breast cancer," given the debate that continues to surround this hypothesis. Finally, one panelist recommended that the profile should note that pre-menopausal and post-menopausal breast cancers might have different etiologies.

As noted earlier, additional comments regarding the profile's handling of breast cancer can be found in Section 3.2.4, above.

**Comments on PCBs and Non-Hodgkin's Lymphoma.** A public comment thought the profile grossly overstated the findings of the Hardell study on the links between PCBs and non-Hodgkin's lymphoma (Hardell et al., 1996). Two panelists agreed with this comment. Noting that the Hardell study did not directly examine immune markers or any other immune effects, one panelist thought the profile should not state that this study's "... data suggest that the immunosuppressive effects of PCBs may relate to the etiology of non-Hodgkin's lymphoma" (page 139). This panelist instead thought the profile should simply state the main finding of the Hardell study—elevated PCB levels were found to be associated with some cases of non-Hodgkin's lymphoma. The other panelist did not think the profile should report hypothetical mechanisms, especially when little evidence of the mechanisms exist.

The panelists discussed several general issues related to the profile's discussion on non-Hodgkin's lymphoma. First, noting that immunosuppression accounts for a very small portion of non-Hodgkin's lymphoma cases, one panelist emphasized that the absence of evidence linking PCBs to immunosuppression does not necessarily contradict apparent associations between PCBs and non-Hodgkin's lymphoma. Second, though the mechanisms of action might not be known, two panelists thought the profile should
underscore the consistent findings of the Hardell study and selected occupational studies (e.g., Betrazzi et al., 1987). One panelist added that the absence of consistent evidence across every occupational study might simply result from the rarity of non-Hodgkin's lymphoma, and not from a lack of association between PCBs and this cancer. Third, the panelists suggested additions to the profile’s section on mechanisms of PCBs and non-Hodgkin's lymphoma: One panelist indicated that this mechanism is clearly not Ah receptor mediated; another panelist thought the profile should acknowledge other potential mechanisms (e.g., immunosuppression and reactive oxygen species) for all types of cancers, but some panelists cautioned about including too many hypotheses and theories on cancer mechanisms in the profile.

**Public Comment on the Rothmann Study (1997).** A public comment recommended that the profile note that Rothmann’s 1997 research on non-Hodgkin’s lymphoma was conducted primarily to generate hypotheses and that further research is required to confirm its theories. A panelist clarified that the Rothmann study was not designed to generate hypotheses; rather, the study’s original design was reportedly to examine associations between cancer outcomes and DDT, but the study happened to generate hypotheses by virtue of its findings specific to PCBs. No other panelists addressed this comment.

**Public Comment on Sensitivity of Younger Animals to Carcinogenic Effects of PCBs.** A public comment indicated that experimental studies do not suggest that younger animals have greater sensitivity to carcinogenic effects of PCBs. Two panelists disagreed with this comment, however, noting that Dr. Lucy Anderson has published several studies documenting differential sensitivity of immature animals to PCB-related carcinogenic effects (Anderson et al. 1983, 1986, 1993). Further, another panelist noted that studies by Rao and Banerji have characterized PCB-related carcinogenic effects in 5-week old rats,
though these studies did not compare the sensitivity of the immature rats to adult rats (Rao and Banerji 1988).

- **Public Comment on the Bahn et al. Study (Bahn et al. 1976, 1977).** Noting that Bahn’s study is in fact a letter to the editor that reports preliminary data, a Submitter suggested that the profile place a lesser emphasis on its results. One panelist thought this particular letter to the editor was an important contribution to the literature, even though Bahn’s study results were never published. No other panelists commented on this study.

- **MRLs and Cancer Endpoints.** One panelist wondered if ATSDR will derive an MRL or some other advisory limit that reflects carcinogenic endpoints. Other panelists and ATSDR scientists explained that the MRLs, by definition, are based strictly on non-carcinogenic effects and that ATSDR, as per policy, does not derive advisory limits for cancer effects. Rather, the Agency simply defers to EPA’s cancer slope factors for such limits, if appropriate.

- **General Comments on PCBs and Cancer.** When reviewing the profile’s treatment of PCBs and cancer, some panelists made general comments that do not fit under the categories described above. Examples of these comments follow: (1) One panelist thought the toxicological profile’s summary of Rothmann’s paper overlooked a notable finding—a potential interaction between cancerous effects and the Epstein-Barr virus. (2) One panelist noted that IARC’s document on the carcinogenicity of dioxin reviews studies of cancer among the Yusho and Yu-Cheng populations that might be relevant for the profile on PCBs (Hsu et al. 1985; Kuratsune et al. 1987). (3) One panelist thought the discussion of breast cancer on pages 138 and 139 was unclear, because it did not clearly distinguish the study of fisheaters from the study of blood donors. (4) One panelist indicated that the review of the Mayes animal study should note that dibenzofurans were largely removed
3.2.6 Reproductive Effects

The panelists stepped through the three public comments regarding reproductive effects. They had no comments on ATSDR’s proposed disposition of two comments, but they did discuss the proposed disposition of the third. An overview of this discussion, plus general comments on PCB-related reproductive effects, follow:

- **Public Comment on the Presentation of Endometriosis Studies.** A public comment took exception to how the profile presented information on PCBs and endometriosis, particularly the profile’s suggestion that “... endometriosis is known to occur following exposure to dioxin and some dioxin-like chemicals” (page 122). One panelist thought the profile should include a summary of studies that link dioxin to endometriosis, so long as the profile clearly acknowledges that links between PCBs and endometriosis have not been identified. However, noting that the mechanisms of action of dioxins and coplanar PCBs are similar, this panelist indicated that the lack of information on PCBs and endometriosis does not necessarily imply that the two are completely unrelated.

When discussing this topic, one panelist cited results from Arnold’s study on endometriosis in rhesus monkeys: The study reportedly found no correlation between PCB exposure and the incidence of endometriosis, but the study found that monkeys who were fed Aroclor
1254 had longer average menses duration and a shorter average menstrual cycle length than the untreated monkeys (Arnold et al., 1996). Noting that the group of monkeys considered in this study was relatively old, one panelist suggested that a similar study of a younger group of monkeys might generate different results. No other panelists commented on the potential links between PCBs and endometriosis.

• General Comments on Reproductive Issues. One panelist thought the profile should have commented more thoroughly on the findings of the Michigan fisheater study that are relevant to reproductive effects, such as the observed late fetal loss, changes in menstrual cycles, and time-to-pregnancy effects. Noting that some of these findings are currently classified under developmental effects (Section 2.2.2.6), this panelist recommended that the profile clearly state how ATSDR distinguishes research on developmental from research on reproductive effects. Another panelist recommended that the profile document Barsotti’s findings regarding reduced reproductive performance in rhesus monkeys up to 5 years following the cessation of dosage of Aroclor 1248 (Barsotti et al., 1976).

3.2.7 Toxicokinetics
Most of the panelists did not comment on Section 2.3 of the profile. As an exception, one panelist recommended that ATSDR review its statements on distribution of PCBs to reflect the most recent information available, particularly congener-specific data. This panelist thought the profile had confusing statements on serum-adipose partitioning (page 160) and should have offered more detail on distribution of PCBs following oral exposure. He thought the profile’s treatment of metabolism was adequate.

3.2.8 Mechanisms of Action
When reviewing information on the toxicological endpoints, the panelists offered two general comments on Section 2.4 that are not listed in the previous subsections. First, one
panelist recommended that the section on mechanisms of toxicity acknowledge the research by Isaac Pessah on the ryanodine receptor (Pessah 1997; Wong and Pessah 1996, 1997). This panelist believed Pessah’s work has noteworthy implications both because it points to a receptor-mediated mechanism for the non-dioxin-like PCB congeners and because the structure-activity data for this receptor correlate with the structure-activities for selected neurotoxic effects.

Second, two panelists strongly disagreed with the statement in the profile, “Most of the non-neural toxic and biochemical effects of PCBs occur via a signal transduction pathway involving the Ah receptor” (page 197). They believed that most of these effects occur via pathways that do not involve the Ah receptor and suggested some of these pathways be discussed in the profile.

3.2.9 Reducing Peak Absorption Following Exposure

One panelist recommended, and another agreed, that ATSDR delete or thoroughly revise Section 2.11.1 (Reducing Peak Absorption Following Exposure) because he was unaware of any method, except possibly for lactation, that effectively reduces PCB body burdens in exposed individuals. Another panelist agreed that medical intervention cannot reduce PCB body burdens, but he added that physicians can offer recommendations for minimizing the toxic effects of exposures.

3.3 Comments on Chapter 3—Chemical and Physical Information

The expert panel reviewed ATSDR’s proposed disposition of the two public comments relevant to Chapter 3 and offered general comments on the chapter. A summary of the panelists’ discussions follows:

- **Public Comment on “Heavy 1254.”** A public comment recommended that Chapter 3 include information on “heavy 1254”—a PCB congener mixture similar to Aroclor 1254, but containing higher amounts of dioxin toxic equivalents. One panelist agreed with the comment, particularly because the congener profile for any mixture affects the results and
interpretations of human and animal studies. This panelist recommended that the profile indicate the relative toxicity of “heavy 1254,” to the extent that such information is available.

- Public Comment on Revising Table 3-5. A public comment recommended that ATSDR update Table 3-5 in the profile with more recent information on the congener composition of various Aroclors. The panelist who provided the updated information noted that the data were originally compiled by George Frame, and recommended that ATSDR cite his effort if the Agency uses the revised table in the final profile (Hansen 1999).

- General Comments on Chapter 3. The panelists offered several general comments on the profile’s presentation of chemical and physical properties of PCBs. First, two panelists thought Chapter 3 should include text that describes, even if generally, how the various chemical and physical properties of PCBs affect environmental distribution and the potential for human exposure. These panelists also recommended that the profile indicate how PCB properties are, to a certain extent, dependent on the number of chlorine atoms in a given congener (e.g., lower-chlorinated PCBs tend to be more water soluble and volatile than the higher-chlorinated PCBs), though they acknowledged that such information could also be logically presented in other chapters of the profile.

An observer indicated that the profile incorrectly identifies the reasons why PCBs were originally used in industry (page 274). This observer noted that fire resistance, rather than chemical inertness, was the primary factor for selecting PCBs for various applications. Consequently, this observer took exception to the profile’s characterization of PCBs as “combustible liquids” (also on page 274). ATSDR’s profile contractor suspected that this characterization was taken from a Department of Transportation designation of PCB properties, but no panelists or observers could confirm this explanation.
Based on an observer comment, one panelist recommended that the profile provide more detailed information on the chemicals that can be formed upon combustion of PCBs. The observer acknowledged that data suggest that PCBs form furans upon combustion, as the profile indicates, but he did not think sufficient data were available to confirm that PCBs form dioxins. This observer noted that model compound studies have suggested that chlorinated benzenes, which are often found in PCB mixtures, form dioxins upon combustion, but he was unaware of any similar studies suggesting that PCBs form dioxins. Questioning this position, a panelist thought studies of the Yusho incident reported that trace amounts of dioxins were formed upon heating PCB mixtures, but the observers indicated that most of the data suggested otherwise and that only very limited data of questionable quality indicated that PCBs might form dioxins. Overall, the observers and some panelists recommended that ATSDR review its discussion of combustion by-products accordingly (page 274).

Finally, after discussing the history of how PCBs have been used in industry, one panelist recommended that the profile mention the different chemicals, such as chlorobenzenes, that are commonly found in PCBs. This suggestion followed an observer comment on past use of Askarels—a generic grouping of non-combustible electrical fluids that contained PCBs and often, though not always, contained chlorobenzenes. Also relevant to this discussion was the observation that many companies altered the composition of PCB mixtures that were originally prepared by manufacturers.

3.4 Comments on Chapter 4—Production, Import/Export, Use, and Disposal

The panelists reviewed the nine public comments ATSDR received on topics in Chapter 4 and the Agency’s proposed disposition of these comments. With one exception, the panelists and observers had no additional comments on these topics. Two panelists, however, agreed with the public comment suggesting that ATSDR should consider deleting the entire last paragraph in
Chapter 4 (pages 303 and 304), which addresses remedial options for PCB-contaminated sites. The Submitter and the two panelists were concerned that, in this paragraph, ATSDR was “identifying preferred remedial alternatives”—an issue that EPA typically addresses. One panelist suggested that ATSDR merely present the various remedial options without commenting on which options are preferred.

An ATSDR scientist provided one additional comment on Chapter 4, suggesting that ATSDR reconsider including discussions on specific clean-up levels for PCBs in soils (page 302), since some readers might infer that the listed levels should apply to all PCB-contaminated sites. If ATSDR retains the information on soil clean-up levels, one panelist recommended that the profile indicate the soil depth over which these levels apply.

3.5 Comments on Chapter 5—Potential for Human Exposure

The expert panel and observers discussed selected public comments ATSDR received on Chapter 5 of the profile. A summary of this discussion follows:

- Clarification of Exposures Due to Fish Consumption. One panelist strongly recommended that ATSDR reconsider the profile’s summary statements about how the general population is exposed to PCBs. This panelist emphasized an important distinction that the profile should make: Consumption of fish caught in PCB-contaminated waters leads to notably different exposures than consumption of fish purchased in stores. Moreover, this panelist added that the general population primarily consumes tuna, shrimp, catfish, and salmon, all of which reportedly have extremely low PCB levels or no measurable PCBs. Another panelist agreed with this comment.

- Public Comment on the Reported Serum Levels of PCBs. A Submitter recommended that ATSDR provide additional context for the serum levels of PCBs (4–8 ppb) reported in
the toxicological profile. Some panelists strongly agreed with this sentiment. One suspected that the reported serum levels are based on relatively old data and should be updated with recent figures, if available. After emphasizing that the reported serum levels can have great implications on current public health studies, this panelist recommended that ATSDR carefully consider this public comment and properly caveat the estimated serum levels as necessary. Further, an observer thought the profile should indicate that PCB serum levels generally increase with age. Finally, two panelists suggested that Health Canada might have more recent data for commenting on serum levels of PCBs.

- Public Comment on the Presentation of Dated Information. Noting that the profile currently cites some dated exposure concentrations, one Submitter recommended that the document clearly differentiate typical exposure concentrations observed in the past from those observed today. Agreeing with this comment, some panelists noted that much of the exposure concentration data in Chapter 5 is dated. For instance, one panelist indicated that the U.S. Food and Drug Administration (FDA) has recently published information on dietary levels of PCBs that the profile does not cite. Reviewing trends in these data, this panelist indicated that current quarterly “market basket” studies now rarely show PCBs at quantitative levels (50 ppb). He added that these current PCB levels are considerably lower than levels that were observed during the 1970s—a trend that several panelists thought the profile should mention. Some panelists wondered whether the average daily intake, when normalized to body weight, suggested by the market basket studies currently exceeds ATSDR’s proposed MRL. This issue was not resolved during the meeting.

- Public Comment on Current Occupational Exposures to PCBs. One Submitter thought the profile included an inaccurate account of current occupational exposures to PCBs (“... occupational exposures to PCBs remains several orders of magnitude higher...
than general population exposure,” page 308). Agreeing with this comment, one panelist noted that elevated PCB body burdens in individuals with occupational exposures might primarily reflect past exposures, and provide little insight into current exposure levels. Based on this and other arguments, some panelists recommended (and an observer agreed) that Chapter 5 better reflect how PCB exposures have changed in occupational settings over the years and specifically identify the occupations that likely have the greatest potential for exposure to PCBs today.

Public Comment on Comparability of Various Human Monitoring Findings. One Submitter suggested that the toxicological profile summarize the significance of the different sampling media (e.g., blood serum, breast milk, and adipose tissue). One panelist indicated that ATSDR could respond to this comment by providing general guidelines for estimating PCB levels in one medium from reported PCB levels in another medium. Other panelists cautioned, however, that such simple partitioning guidelines would likely not apply to all PCB congeners and that congener-specific partitioning has not been extensively documented in the scientific literature.

Public Comment on PCB Exposures via Contaminated Drinking Water. A Submitter took exception to statements in the profile which imply that ingesting contaminated drinking water might be a relevant source of exposure to PCBs (“The general population may be exposed to PCBs by inhaling contaminated air and ingesting contaminated water and food,” page 307). Noting that PCBs are extremely hydrophobic compounds, one panelist agreed with the public comment, even for historical exposures. Another panelist, on the other hand, did not think such statements should be removed from the profile entirely, since “raw water” with high amounts of suspended solids could be a viable exposure pathway for PCBs and since PCBs in water are the major source of contamination to fish. Accordingly, this panelist encouraged that ATSDR acknowledge
(rather than ignore) the various potential exposure pathways for PCBs, and put them into proper perspective.

Public Comment on Atmospheric Removal Processes. A public comment questioned whether photolysis is the dominant removal pathway for airborne PCBs, as the profile currently suggests (page 306). One panelist thought precipitation, not photolysis, is the dominant removal pathway.

General Comments on Chapter 5. When addressing the public comments, the panelists offered the following general insights on the technical content of Chapter 5. First, one panelist thought the profile should clearly indicate that the PCB congener profile in most inhalation exposures considerably differs from that in oral exposures. This panelist also thought the profile's discussion of indoor air exposures places too great an emphasis on PCBs in occupational settings, especially considering that PCBs are now almost never used in industry. Second, one panelist noted that the profile currently uses inconsistent terminology when referring to FDA's tolerance on PCBs in fish. He explained that this tolerance is a regulatory standard (not a guidance) and is based on PCBs in edible tissue (not a lipid-adjusted value). Another panelist, in response to a public comment, recommended that the profile include a reference for its information on PCB degradation in contaminated sewage sludge (page 305). Yet another panelist, when responding to a different public comment, suggested that ATSDR consider data from the National Human Exposure Assessment Survey (NHEXAS), if these data are available.

3.6 Comments on Chapter 6 to Chapter 9

The panelists did not specifically discuss topics in Chapters 6 through 9 of the profile. It should be noted that ATSDR received very few public comments on Chapters 6 and 7, and no public comments on Chapters 8 and 9.
3.7 Comments on Appendix A—ATSDR Minimal Risk Levels and Worksheets

The panelists discussed at length the scientific basis of ATSDR's proposed approach for deriving MRLs for PCBs. The draft toxicological profile includes only a chronic oral MRL (0.02 μg/kg/day), which is based on immunological effects observed in rhesus monkeys. Before the panelists commented on the MRL for PCBs, ATSDR distributed handouts that define the MRL and how it is typically derived, including how uncertainty factors enter into MRL derivations. After the panelists reviewed this information, they discussed many topics relevant to the MRL for PCBs.

Overall, the panelists' discussion raised several important issues. First, though the panelists generally approved of ATSDR's derivations of the MRL based on the Tryphonas study (see Section 3.7.1 of this report), they highly recommended that ATSDR consider the Tilson study of human cohorts as a supplemental basis for the MRL. This study is reviewed in Section 3.7.2, below. Moreover, the panelists recommended that ATSDR consider an additional animal study as a basis for developing an intermediate oral MRL. Section 3.7.3 of this report summarizes their discussion regarding this study by Dr. Deborah Rice. Section 3.7.4 then reviews general comments the panelists made when discussing MRLs for PCBs, including mention of an additional human study that could be used to derive the MRL, but was not reviewed extensively during this discussion.

As reviewed below, the panelists suggested ATSDR conduct evaluations of studies in addition to the Tryphonas study to support the proposed MRL. Specifically, the panelists presented some information suggesting that neurological endpoints might be more sensitive than immunological endpoints and therefore a more appropriate basis for the MRL. The panelists reached no conclusions on this hypothesis, though, due to recognized limitations in the human study by Tilson et al. and questions regarding ATSDR's use of uncertainty factors. Nonetheless, the panelists underscored the fact that the dose-response data from two considerably different
studies (and possibly more) paint a very consistent picture regarding health-guidance values for PCBs: An animal study and a human study, both of which considered different exposure doses and toxicological endpoints, suggest notably similar chronic oral MRL levels. The panelists recommended that ATSDR carefully evaluate the strengths and limitations of both studies before proposing its final chronic oral MRL for PCBs.

The observers made no comments on the panelists' discussion of MRLs.

3.7.1 Tryphonas Study (Tryphonas et al. 1989, 1991a)

Before the panelists discussed the public comments on ATSDR's proposed MRL, the Chemical Manager for the Toxicological Profile for PCBs described how ATSDR derived the chronic oral MRL for PCBs from the research conducted by Dr. Helen Tryphonas. The Chemical Manager explained that this study examined immunological effects among female rhesus monkeys that were exposed to Aroclor 1254 for 55 months. In general, monkeys that received Aroclor 1254 doses as low as 0.005 mg/kg/day had significant reductions in immune responses to challenges of sheep red blood cells, while monkeys that received no doses did not have impaired immune responses. Therefore, the study reported a lowest-observed-adverse-effect level (LOAEL) of 0.005 mg/kg/day. The Chemical Manager then explained why ATSDR proposed applying three uncertainty factors to this LOAEL to derive an MRL: The Agency used a factor of 10 to extrapolate the LOAEL to a no-observed-adverse-effect level (NOAEL); a factor of 3 to extrapolate from animal studies to humans; and a factor of 10 to account for human variability. Accounting for these factors, the Chemical Manager noted that ATSDR proposed a chronic oral MRL of 0.02 μg/kg/day.

Some panelists highlighted the strengths of the Tryphonas study. For instance, one panelist noted that the study used a relatively large sample size, especially when compared to other studies involving rhesus monkeys. Another panelist added that the Tryphonas study was very carefully
controlled and provides data on immunological effects for a wide range of PCB doses, while controlling for confounding factors that are unavoidable in human studies (e.g., exposures to other persistent, bioaccumulative toxins). After extensive debate and discussion on the merits of this study, none of the panelists identified critical shortcomings of the Tryphonas study.

The expert panel subsequently reviewed the public comments that ATSDR received on this study, and Dr. Tryphonas herself provided key insights to her work. An overview of these comments, and the panelists' responses, follows:

- **Public Comment on the Improper Selection of Toxicologic Endpoint for the MRL.**
  
Based on concerns regarding the Tryphonas study (as outlined below), one public comment suggested that ATSDR should not base its chronic oral MRL on the immunotoxicity of PCBs. None of the panelists agreed with the Submitter's criticisms, and Dr. Tryphonas was particularly confident that the immunological endpoint was an appropriate basis for ATSDR's MRL. Dr. Tryphonas acknowledged that evidence of PCB-related immunotoxicity has not been closely monitored in human studies. Nonetheless, she noted that many human studies provide accounts of adverse immunological effects following exposures to PCBs. As examples, she highlighted findings of relevant human studies:

Children born to women in Michigan and Wisconsin who ate fish from the Great Lakes suffered from higher incidence of infections (primarily bacterial) during their first 4 months of life, when compared to other infants (Swain 1991); infants born to women who were exposed to Kanechlor 500 and Kanechlor 300 had a higher incidence of colds and other infections when compared to infants born to women who were not exposed to these Kanecholors (Hara 1985); and 6-year old children from the Yusho and Yu-Cheng incidents had a higher incidence of bronchitis and ear infections, thus suggesting an immunological
impairment (Chao et al. 1997; Rogan et al. 1988). Though she noted that the aforementioned human studies all have limitations preventing one from concluding that PCBs cause immunological effects in humans, Dr. Tryphonas felt that the combined evidence from these and other studies suggest that PCBs are indeed toxic to the human immune system and that basing the MRL on immunotoxic effects is entirely appropriate.

Another panelist agreed with Dr. Tryphonas’ arguments. He added that his experience as a researcher for EPA on Aroclor 1254 has found that immunotoxicity is a critical adverse effect associated with exposure to PCBs. This panelist noted that the Levinskas study found a dose-response relationship for clinical manifestations of PCB-related immunotoxicity in rhesus monkeys (Levinskas et al. 1984). Based on this study and other studies, this panelist was also convinced that basing the MRL on immunotoxic effects was appropriate.

- **Public Comment on the Clinical Relevance of the Tryphonas Study.** One public comment suggested that ATSDR not base its MRL on the Tryphonas study because the observed immunological effects have little clinical relevance to humans. Dr. Tryphonas again disagreed, for several reasons. First, she defended her choice of the sheep red blood cell antigen partly due to its widespread use in animal studies to characterize immunotoxic effects of pollutants. In fact, Dr. Tryphonas noted that the Organization for Economic Cooperation and Development (OECD) recently proposed the use of the plaque-forming

---

1 Dr. Tryphonas indicated that the children considered in the Yusho and Yu-Cheng incidents did not have abnormally low levels of natural killer (NK) cells or immunoglobulin. However, Dr. Tryphonas noted that the NK cell numbers do not necessarily correlate with the functional activity of the NK cells and that immunoglobulin levels typically are only lowered by "great insults" to the immune system. Therefore, she concluded that people with normal NK cell numbers and immunoglobulin levels might still have compromised immune function. Similarly, Dr. Tryphonas also explained why a study of immunotoxic effects in transformer repairmen found negative results (Emmett et al. 1988): She noted that this study's negative results were for secondary immune responses, and that examining changes in secondary responses might fail to identify important effects to the primary (humoral) response.
cell assay, which contains the sheep red blood cell antigen, as a standard functional assay for testing the immunotoxic effects of chemicals in animal studies.

Second, Dr. Tryphonas indicated that other researchers have reported that immune responses to the sheep red blood cell antigen in animals are highly predictive of these animals’ responses to selected infectious agents (Luster et al. 1988, 1992). Moreover, her ongoing research on the immunotoxic effects of toxaphene has indicated that Cynomolgus monkeys have immune responses to the tetanus toxoid comparable to the responses to sheep red blood cells, thus providing evidence that animal responses to the sheep red blood cells might be clinically relevant to the toxins that humans encounter.

Finally, Dr. Tryphonas explained that the general mechanism of the primary immune response to the sheep red blood cell in rhesus monkeys (e.g., uptake of the antigen, incubation of the macrophage, presentation of the antigen to T-cells, and subsequent production of antibodies) is similar to the humoral response expected to occur in humans. However, noting that researchers will likely never conduct human testing with sheep red blood cells, Dr. Tryphonas acknowledged that the clinical relevance of humans’ immune response to sheep red blood cell antigens can only be hypothesized and not quantified.

For these reasons, Dr. Tryphonas believed that the implications of her research are clinically relevant to humans. Other panelists did not comment on this topic.

- Public Comments that Rhesus Monkeys are a Poor Model of PCB Toxicity in Humans. Two public comments argued that rhesus monkeys and humans have different metabolic pathways for PCBs, which, in turn, lead to different health effects in exposed rhesus monkeys and humans. The Submitters thus concluded that the immunologic effects
observed in rhesus monkeys might be completely irrelevant to humans. None of the panelists agreed with this comment, as described below.

First, Dr. Tryphonas discussed the Submitters’ assertion that rhesus monkeys are more sensitive to PCBs than humans. Noting that this comment on sensitivity is apparently based on information documented in an abstract ("Gillis and Price, 1996"), and not in the peer-reviewed literature, Dr. Tryphonas questioned the validity of the assertion. On another note, Dr. Tryphonas did not agree that pathways for PCB metabolism differ qualitatively between rhesus monkeys and humans, as one Submitter suggests. In fact, according to her own research, the congener profile of PCBs measured in rhesus monkeys that are fed a mixture of PCB congeners typically found in human breast milk tends to match closely the profile observed in humans. Even if qualitative metabolic differences existed, however, Dr. Tryphonas still cautioned that they would not necessarily imply that rhesus monkeys are somehow more sensitive to PCBs than humans.

Other panelists provided additional insight on this public comment. For instance, based on the study by Tilson et al. (see Section 3.7.2, below), one panelist noted that published research has suggested that rhesus monkeys might actually be less sensitive than humans for developing PCB-related health effects—in this case, behavioral or neurodevelopmental effects. Another panelist agreed, and added that his experience reviewing animal studies has not suggested a considerable sensitivity among rhesus monkeys to PCBs.

- Public Comment on the Proposed Uncertainty Factors for the MRL. One public comment suggested that the chronic oral MRL for PCBs should be based only on an
overall uncertainty factor of 30, instead of 300.\(^2\) Noting that her study examined immunological effects only among middle-aged rhesus monkeys, Dr. Tryphonas advocated the use of conservative uncertainty factors for deriving the MRL, since certain human groups—children, the elderly, and immunosuppressed populations—might be much more susceptible to PCB-related immunological effects; she thought an uncertainty factor of 300 was appropriate. Another panelist agreed, and recommended the Agency continue to use an overall uncertainty factor of at least 300; yet another panelist thought a case could be made for applying an additional uncertainty factor of 10 (for a total factor of 3,000) to account for children’s susceptibility. On the other hand, because the Tryphonas study considered some elderly rhesus monkeys, one panelist added that a case can be made for using less conservative uncertainty factors.

• Public Comment on the Representativeness of an MRL Based on Exposure to Aroclor 1254. One Submitter noted that the Tryphonas study used doses of unweathered Aroclor 1254, rather than doses of weathered PCBs, like those typically observed in the environment. Speculating that weathered PCBs are more toxic than the unweathered mixtures, this Submitter thought the MRL based on the Tryphonas study might understate risks of ingesting PCBs. Disagreeing with the Submitter’s reasoning, one panelist did not think the available environmental sampling and toxicological data supported a blanket judgment that weathered PCBs in the environment are indeed more toxic than unweathered Aroclor 1254. As a result, this and another panelist did not agree with the Submitter’s comment. No other panelists commented on this issue.

\(^2\) Technically, the Submitter’s recommendation was that the MRL should be based on the dermal, ocular, and nail effects observed in the rhesus monkeys of the Tryphonas study. The Submitter proposed using an uncertainty factor of 30 for an MRL based on that endpoint. However, the panelists’ comments focused on the use of uncertainty factors for the endpoint of immunological effects. In response to an earlier comment, the panelists agreed that basing the MRL on immunological effects was appropriate.
3.7.2 Tilson et al. Study 1990

Dr. Walter Rogan recommended that ATSDR consider deriving its MRL based on the findings of the study by Tilson et al., which included Dr. Rogan as a contributing author (Tilson et al., 1990). This study examined neurodevelopmental effects in cohorts of children in Michigan and North Carolina and reported a NOAEL for 95 percent of the cohort of 0.093 μg/kg/day—a NOAEL that represents the estimated daily dose that mothers can receive before adverse neurodevelopmental effects are observed in their offspring. The mothers in this study were not exposed to PCBs in occupational settings. Before the panelists commented on this recommendation, Dr. Rogan briefly reviewed key aspects of the Tilson study.

Dr. Rogan explained that this study used various metrics (e.g., the Brazelton Neonatal Behavioral Assessment Scale or the Bayley Scales of Infant Development) to determine whether children in the two cohorts developed normally or abnormally. Based on the motor development index, which quantifies children’s abilities to stack blocks, dump raisins out of bottles, and so on, Dr. Rogan found that the children whose mothers had PCB concentrations in breast milk fat of 3.4 ppm or greater had statistically significant lower test results than the other children in the cohorts. In short, the breast milk fat concentration of 3.4 ppm was the highest PCB level in mothers below which no adverse health effects were observed in their children. This general trend was reportedly observed among the children at age 6 months, 12 months, 18 months, and 24 months, and was also observed for various other development metrics (e.g., fourth grade IQ data). In fact, Dr. Rogan indicated that decreased visual recognition memory actually occurred among children whose mothers’ breast milk fat concentration was 1.0 ppm, but this metric was used only in the Michigan cohort and not in the North Carolina cohort.

Because PCB doses were not measured in the Michigan and North Carolina studies, the researchers had to estimate the daily exposure of PCBs that would result in a mother having a breast milk fat concentration of 3.4 ppm at the time of delivering a child. Dr. Rogan listed the
computational steps and assumptions that were made to estimate this dose. First, the researchers estimated that a 25 year old woman who weighed 60 kg, had 25 percent body fat, and had 3.4 ppm of PCBs in her breast milk, likely had an overall body burden of 51 mg of PCBs. Dr. Rogan indicated the assumptions that were made in this calculation, such as the concentration of PCBs in a woman’s breast milk fat were assumed to be equal to the concentration of PCBs in the fat throughout the rest of the body. Second, assuming that the 51 mg body burden is a result of a lifetime of low-level PCB exposure without any excretion, the researchers estimated that women with 3.4 ppm in their breast milk fat had an average daily PCB intake of 5.6 μg/day. Normalizing this to the average body weight of a 25-year-old woman (60 kg), this daily intake translates into a daily dose of 0.093 μg/kg/day—the dose that Dr. Rogan and his colleagues reported as a NOAEL for neurodevelopmental effects.

Before the panelists commented on this study, Dr. Rogan listed several uncertainties associated with his dose calculations. First, because losses of PCBs through excretion, lactation, and metabolism were not factored into the dose calculations, the actual dose that results in 3.4 ppm of PCBs in breast milk fat would be higher than the reported NOAEL. Second, if dose calculations were based on women older than 25 years, the estimated daily dose would be lower than the reported NOAEL. Moreover, a difference in the analytical methods used in the Michigan study and the North Carolina study (i.e., the “2-peak” versus the “6-peak” methods) also might have caused the researchers to overestimate the actual NOAEL, possibly by a factor of 2.

Following this presentation, the panelists and ATSDR scientists discussed whether the Tilson et al. 1990 study can serve as an alternative basis for the chronic oral MRL. Some panelists noted that the data from the Tilson study provide a very realistic account of environmental exposures, since the study considered humans who are exposed to low-level PCB doses through their everyday activities. However, other panelists highlighted corresponding limitations, such as the fact that the subjects in the Michigan and North Carolina studies were
undoubtedly exposed to many other persistent, bioaccumulative toxins (e.g., dioxins) that might account, at least in part, for the observed health effects. In short, some panelists cautioned that one cannot be certain that the health effects resulted directly from PCB exposure, even though the study’s evidence strongly suggests this is the case. Finally, some panelists recommended that ATSDR consider the uncertainties inherent in back-calculating exposure doses when considering the Tilson et al. 1990 study as a basis for the chronic oral MRL—a potential shortcoming that does not apply to the carefully controlled animal studies.

Some panelists debated which uncertainty factors should be applied to the reported NOAEL to derive an MRL. Some suggested using only a factor of 10 to account for intra-species variability, but others suggested using an additional factor of 10 to account for children as a sensitive population. As Section 3.7.4 notes, the panelists discussed the applicability of this additional factor at length, but did not agree on the appropriateness of this factor for deriving an MRL. Despite these debates, several panelists noted that the NOAEL reported by Tilson et al. 1990 (0.1 μg/kg/day, when rounded to one significant digit) is comparable to ATSDR’s extrapolation of a NOAEL in humans from the Tryphonas study (0.2 μg/kg/day). Recognizing the similarity in these levels, some panelists thought ATSDR should stress that its final MRL can be defended both by considering immunological effects in rhesus monkeys and neurodevelopmental effects in humans. In other words, some panelists recommended that ATSDR use a weight-of-evidence approach in developing its MRL.

Two notes deserve mention. First, Dr. Rogan provided evidence that his NOAEL might be overstated by a factor of two, due to the use of an analytical method that is known to overstate PCB concentrations. As a result, a NOAEL of 0.05 μg/kg/day can be reported for the Tilson study for the most sensitive population (i.e., embryos and children). (Note, some panelists thought an additional factor of 10 should be applied to his NOAEL to account for sensitive populations, but other panelists disagreed.) Second, the extrapolated NOAEL for the Tryphonas study was derived as follows: The LOAEL in rhesus monkeys of 5.0 μg/kg/day was divided by 3 to account for inter-species uncertainty and then by 10 to convert a LOAEL to a NOAEL. An additional factor of 10 was applied to the Tryphonas study to account for the most sensitive populations, thus generating a NOAEL of 0.02 μg/kg/day. Therefore, the NOAEL presented in the draft toxicological profile (0.02 μg/kg/day) is lower than that derived from the Tilson study.
Regardless of whether ATSDR eventually adopts the Tilson study as the basis for its MRL, the panelists suggested that the NOAEL dose from the North Carolina study should at least be cited in the toxicological profile's LSE tables.

3.7.3 Rice Studies

Several panelists and the Submitter of a public comment suggested that ATSDR consider the findings from Dr. Deborah Rice's recent studies on behavioral effects in monkeys as a basis for an intermediate oral MRL (Rice, 1999a; 1999b). These panelists briefly summarized Dr. Rice's study, which reportedly considered doses of mixtures of PCBs at 7.5 μg/kg/day for 20 weeks to infant monkeys. According to the panelists, this dose level is comparable to that which can be observed environmentally. The monkeys were then tested for various behavioral effects at ages of 2.5 and 5 years. According to the panelists familiar with this research, Dr. Rice's study observed that the exposed monkeys had significant behavioral deficits in numerous cognitive tests. These deficits include, but are not limited to, slowed learning and decreased performance on delayed spatial learning and memory tests.

Several panelists thought this study provides an adequate basis for deriving an MRL. Specifically, since the duration of exposure in this particular study was 20 weeks, the panelists noted that Dr. Rice's findings are an appropriate basis for an intermediate oral MRL.

3.7.4 Additional Comments on MRLs

In addition to the specific comments on the Tryphonas, Tilson, and Rice studies, the panelists addressed several other issues pertaining to MRLs for PCBs, as summarized below:

- **Consideration of the Dutch Cohort Studies as an Alternative Basis for the Chronic Oral MRL.** Several panelists thought ATSDR should consider basing its chronic oral MRL on data recently published for the Dutch cohorts (Huisman et al. 1995; Koopman-
Esseboom et al. 1994, 1996a, 1996b; Lanting et al. 1998a, 1998b, 1998c, 1998d; Pantandin et al. 1997, 1998a, 1998b, 1998c, 1998d, 1999a, 1999b; Weisglas-Kuperus 1998). Though the panelists did not specify which endpoint was found to be most sensitive in these cohorts, one panelist thought the Agency might be able to develop dose-response relationships for thyroid effects among the subjects.

When reviewing the Dutch cohort study, some panelists identified a critical potential confounding factor: The human subjects were exposed to many chemicals of concern, including persistent, bioaccumulative toxins other than PCBs (e.g., dioxins). One panelist noted that the Dutch study reported that some adverse effects correlated with the combined exposure of dioxins and PCBs, while other effects correlated strictly with PCB exposures. As an example, this panelist indicated that learning effects among 4-year-olds were found to be PCB-specific. Despite this finding, several panelists agreed that working with the combined exposures to PCBs and dioxin might be complicated, but these panelists thought ATSDR should at least investigate the relevance of the data from the Dutch cohort studies for developing a chronic oral MRL.

Public Comment on Carcinogenic Effects and MRLs. A public comment suggested that ATSDR's failure to consider carcinogenic effects when developing the MRL was "a mistake or serious oversight." ATSDR scientists explained that the MRLs, by definition, do not account for cancer effects. The panelists discussed at length various pros and cons of this approach—a discussion that focused primarily on ATSDR's health guideline policies and not specifically on PCBs, and is therefore not summarized in this report.

Use of Uncertainty Factors that Account for Children's Exposures. Several panelists asked about the need for including additional uncertainty factors that account for children's sensitivity to PCB exposures. ATSDR scientists explained that the Agency's mandate is to
consider use of such additional factors when developing health guidance values (i.e., the Agency is not required to use these factors) and that the origin of this mandate was for evaluating pesticide chemical residues, and not for PCBs. Nonetheless, some panelists recommended that ATSDR consider applying an additional uncertainty factor of 10 to the proposed MRL to protect children. Other panelists disagreed, noting that the uncertainty factor of 10 for intra-species variability was sufficient for this purpose.

- Public Comment on an MRL Based on Other Endpoints. One public comment suggested that ATSDR consider basing its chronic oral MRL on the reproductive and developmental effects observed in an animal study by Arnold (Arnold et al. 1995). The Submitter argued that the results of this study suggest an MRL of 0.5 µg/kg/day. None of the panelists advocated the use of this MRL, presumably because the MRLs based on the studies discussed in Sections 3.7.1 and 3.7.2 are both considerably lower than the MRL derived using the Arnold study.
4.0 REFERENCES


Expert Review of the Toxicological Profile for PCBs


4-5


APPENDIX A
LIST OF PARTICIPANTS
List of Participants and Observers
for the Expert Panel Review for PCBs
(September 27 - 29, 1999)

Updated as of September 24, 1999

PARTICIPANTS

Annette E. Ashizawa, M.P.H., Ph.D.
Visiting Scientist
Division of Toxicology/Research Implementation Branch
1600 Clifton Road, NE
Mail Stop E-29
Atlanta, GA 30333
Tel: (404) 639-5093
Fax: (404) 639-6315
email: ada8@cdc.gov

Mike Bolger, Ph.D.
Contaminants Branch
Mail Code HFS-308
FDA
200 C Street, S.W.
Washington, DC 20204
Tel: (202) 205-8705
Fax: (202) 260-0498
email: mbolger@bangate.fda.gov

Stephen Bosch, B.S, Profile Co-Author
Syracuse Research Corporation
6225 Running Ridge Road
North Syracuse, NY 13212
Tel: (315) 452-8405
email: Bosch@Syrres.com

Frank J. Bove, Sc.D.
Sr. Epidemiologist
Agency for Toxic Substances and Disease Registry
Division of Health Studies
Mail Stop E-31
Atlanta, GA 30333
Tel: (404) 639-5126
Fax: (404) 639-6219
email: fjb0@cdc.gov
Thomas Darvill, Ph.D.
Associate Professor
Department of Psychology
Oswego State University
404 Mahar Hall
Oswego, NY 13126
Tel: (315) 341-3473
Fax: (315) 341-6274
email: darvill@oswego.edu

Christopher De Rosa, Ph.D.
Agency for Toxic Substances and Disease Registry
Director, Division of Toxicology
1600 Clifton Road, NE, Mailstop E29
Atlanta, GA 30333
Tel: (404) 639-6300

Henry Falk, M.D., M.P.H.
ATSDR, Assistant Administrator
1600 Clifton Road, NE
Mailstop E-28
Atlanta, Georgia 30333

Obaid Faroon, Ph.D.
TSDR,
1600 Clifton Road, NE
Mailstop E-29
Atlanta, GA 30333
Tel: (404) 639-6381

Ginger Gist, Ph.D.
Division of Health Studies
ATSDR Mailstop E-31
Atlanta, GA
Tel: (404) 639-5159
Fax: (404) 639-6220

Anthony Gray, Ph.D.
Syracuse Research Corporation
6225 Running Ridge Road
North Syracuse, NY 13212
Tel: (315) 452-8415

Larry Hansen, Ph.D.
Professor
University of Illinois
College of Veterinary Medicine
2001 St. Lincoln Avenue
Urbana, IL 61802
University of Illinois
Tel: (217) 333-6839
Fax: (217) 244 1652
email: lhansen@cvm.uiuc.edu
Expert Review of the Toxicological Profile for PCBs

Heraline E. Hicks, Ph.D.
Sr. Environmental Health Scientist
ATSDR/Division of Toxicology
1600 Clifton Road, NE
Mail Stop E-29
Atlanta, GA 30333
Tel:  (404) 639-5097
Fax:  (404) 639-6315
email: heh2@cdc.gov

Joseph L. Jacobson, Ph.D.
Dept. of Psychology
Wayne State University
71 W. Warren Street
Detroit, MI 48202
Tel:  (313) 875-8550
Fax:  (313) 577-7536
email: jjacobso@sun.science.wayne.edu

Edwin M. Kilbourne, M.D.
Senior Medical Officer
CDC/NCEH
Mailstop F-28
4770 Buford Highway
Chamblee, GA 30341
Tel:  (770) 488-7300
Fax:  (770) 488-7310

Fernando Llados, Ph.D.
Syracuse Research Corporation
6225 Running Ridge Road
North Syracuse, New York 13212
Tel:  (315) 452-8000

Mark McClanahan, Ph.D.
Nat'l. Ctr. Env. of Health
Bldg. 101. Rm. 1425 (MS-F46)
4770 Buford Hwy.
Chamblee, GA 30341
Tel:  (770) 488-7297
Fax:  (770) 488-3506
email: mam4@cdc.gov

Stephanie Miles-Richardson, D.V.M., Ph.D.
Environmental Health Scientist/Endocrine Disruption
Division of Toxicology/Research Implementation Branch
1600 Clifton Road, NE
Mail Stop E-29
Atlanta, Ga 30333
Tel:  (404) 639-5282
Fax:  (404) 639-6315
email: smr7@cdc.gov
Review of the Toxicological Profile for PCBs

John Vena, Ph.D.
Professor
Social & Preventive Medicine
270 Farber Hall
University at Buffalo
3435 Main Street, Bldg. 26
Buffalo, NY 14214
Tel: (716) 829-2975 Ext. 602
Fax: (716) 829-2979
email: jvena@buffalo.edu

John Wheeler, Ph.D., DABT
Division of Toxicology
ATSDR
1600 Clifton Road, NE
Mail Stop E-29
Atlanta, GA 30333
Tel: (404) 639-5280
email: jzw1@cdc.gov

Elizabeth Whelan, Ph.D.
NIOSH
4676 Columbia Parkway
Mailstop R-13
Cincinnati, Ohio 45226
Tel: (513) 841-4203
email: eaw0@cdc.gov

Mary C. White, Sc.D.
Chief, Health Investigation Branch
Division of Health Studies
ATSDR
1600 Clifton Road, NE
Mail Stop E-31
Atlanta, GA 30333
Tel: (404) 639-6229
Fax: (404) 639-6219
email: mxw5@cdc.gov

Malcolm Williams, D.V.M.
ATSDR
1600 Clifton Road, NE
Mailstop E-29
Atlanta, GA 30333
Tel: (404) 639-6380
Expert Review of the Toxicological Profile for PCBs

OBSERVERS

Stephen B. Hamilton, Jr., Ph.D.
Environmental Science
General Electric Company
3135 Easton Turnpike
Fairfield, Connecticut 06431
Tel: (203) 373-3316
Fax: (203) 373-2650

Mr. Brett D. Hulsey (invited to the meeting, but did not attend)
Director, Great Lakes Program
Midwest Representative
Sierra Club
214 North Henry Street
Madison, WI 53702
Tel: (608) 257-4994
Fax: (608) 257-3513

Mr. Robert Kaley
Solutia, Inc.
575 Maryville Centre Drive
St. Louis, MO 63141
Tel: (314) 674-8558
Fax: (314) 674-8808
APPENDIX B

AGENDA
Agenda for the Expert Panel Review of the Toxicological Profile for PCBs

September 27, 1999

**Morning Session**

10:00  Meeting convenes  
Welcome and Introduction:  
Dr. Henry Falk, Assistant Administrator, ATSDR

Review of Agenda and Meeting Objectives:  
Dr. Christopher T. De Rosa, Director, Division of Toxicology

10:15  Developmental Effects (Chapter 2)

12:00  Lunch

**Afternoon Session**

1:00  Continue Developmental Effects Discussion

2:00  Neurobehavioral, Neurodevelopmental, Children (Chapter 2)

3:15  Break

3:30  Endocrine Disruption (Chapter 2)

5:00  Adjourn Meeting
September 28, 1999

Morning Session

8:30  Discussion of Other Health Effects

- Reproductive
- Dermal
- Respiratory
- Other

10:30  Discussion of Chronic Oral MRL and Immunological Effects

- Comparison of studies’ merits as critical MRL study
- Appropriateness of study end-points for use in MRL derivation
- Potential confounders in epidemiologic studies
- Applicability\comparison of end-points across studies
- Critical effects and uncertainty factor selection
- Animal Sensitivities
- Congeners
- PCB planar vs coplanar
- Dioxin-like; phenobarbital-like; estrogen-like PCBs
- Other issues

12:00  Lunch

Afternoon Session

1:15  Discussion of the Following Cancer Issues:

- Weight-of-the-evidence
- Breast Cancer
- GIT Cancer
- Non-Hodgkins Lymphoma
- Hepatocellular Carcinoma
- Melanoma and Squamous Cell Carcinoma
- Yusho and Yu-Cheng incidents and cancer

2:30  Break

2:45  Continue Cancer Discussion
5:00 Adjourn meeting

September 29, 1999

Morning Session

8:30 Review of Chemical and Physical Information (Chapter 3)
Response to Public Comments

9:15 Review of Production, Import, Use and Disposal (Chapter 4)

9:45 Review of Potential for Human Exposure (Chapter 5)

10:30 Review of Analytical Methods (Chapter 6) and Other Issues

11:15 Break

11:30 Discussion of Public Health Statement (Chapter 1)
Response to public comments regarding general issues

12:00 - 12:30 Wrap-up and Next Steps